Compare Lufax Holding Ltd (LU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

LU trades at $0.98, down 0.11% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and ROE. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026. Analyst consensus remains positive with 69% buy ratings, though earnings have consistently missed expectations.

LU presents a deep value opportunity with P/S of 0.25 and P/B of 0.07, but faces significant execution risks amid declining revenue and persistent losses. The company's strong parent backing from Ping An and improving operational cash flow provide some stability, but regulatory headwinds in China's consumer lending market remain a concern for sustained recovery.

Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.

The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.